Published

Two ongoing studies, HIGHLIGHT 1 and OPTION-VMS, include patients with breast cancer, but most of these patients were excluded in earlier trials.

  • The safety and efficacy of fezolinetant in women seeking treatment for vasomotor symptoms (VMS) associated with menopause has been evaluated in Phase 3 clinical trials.1–4
  • A medical history of breast cancer was reported in the DAYLIGHT study in 1.3% of participants receiving fezolinetant 45 mg.5 A family history of breast cancer or mutation of breast cancer (BRCA) gene was reported in the DAYLIGHT study in 17.7% of participants receiving fezolinetant 45 mg, and in < 5% of participants in the SKYLIGHT studies. No subgroup analyses were conducted in these participants.
  • Two studies are ongoing which include women with a medical history of Stage 0 to 3 breast cancer.6–8

  • SKYLIGHT 1 and 2, two identical Phase 3 double blind placebo-controlled 52-week studies, evaluated the safety and efficacy of fezolinetant 30 mg and 45 mg in 1022 women for the treatment of moderate to severe VMS associated with menopause.1,2
  • SKYLIGHT 4, randomized, placebo-controlled, double-blind, Phase 3, 52-week safety and tolerability study further evaluated the safety of fezolinetant in 1830 women seeking treatment for VMS associated with menopause.3
  • DAYLIGHT, Phase 3b randomized, placebo-controlled, double-blind 24-week study, evaluated the safety and efficacy of fezolinetant 45 mg in 452 women with moderate to severe VMS associated with menopause and considered unsuitable for hormonal therapy (HT). 4
  • Inclusion/exclusion criteria relevant to breast cancer in these studies:5
    • SKYLIGHT studies: Participants required a normal clinical breast examination and a normal/negative mammogram; those with a previous or current malignant tumor were excluded, except for basal cell carcinoma.
    • DAYLIGHT study: Participants with a first-degree family history of breast cancer or a BRCA1/2 mutation could be included, but those with a malignant tumor within the previous 5 years were excluded, except basal cell carcinoma.

Medical history in SKYLIGHT studies5

  • A family history of breast cancer or mutation of BRCA gene was reported in the Phase 3 SKYLIGHT studies (Tables 1 and 2).
  • No subgroup analyses of safety or efficacy were conducted in these participants.

Table 1. Medical history of breast cancer in SKYLIGHT 1 and 2 (12-week pre-specified analysis) (Full Analysis Seta)5

Category/Condition

Placebo

(n = 342)

Fezolinetant 30 mg

(n = 339)

Fezolinetant 45 mg

(n = 341)

Family history of breast cancer in first degree relative or mutation of breast cancer gene (BRCA 1 and 2)

12 (3.5%)

8 (2.4%)

6 (1.8%)

aFAS: All randomized participants assessed according to the randomization at first dose.

Table 2. Family history of breast cancer in SKYLIGHT 4 (52-week safety study) (Safety Analysis Seta)5

Hormone Replacement Therapy Status/Category

Placebo

(n = 610)

Fezolinetant 30 mg

(n = 611)

Fezolinetant 45 mg

(n = 609)

Family history of breast cancer

29 (4.8%)

22 (3.6%)

20 (3.2%)

aSAF: All randomized participants who took at least one dose of study intervention.

Medical history in the DAYLIGHT study5

  • A family history of breast cancer or mutation of BRCA gene was reported in the Phase 3 DAYLIGHT study (Table 3).
  • In addition, a medical history of breast cancer was reported for 3.1% (7/226) of participants in the placebo group and 1.3% (3/226) of participants in the fezolinetant 45 mg group.
    • None of the participants had ongoing breast cancer. The time to onset was over five years prior to enrollment in the study.
  • No subgroup analyses of safety or efficacy were conducted in these participants.

Table 3. Family history of breast cancer in DAYLIGHT (24-week study) (Safety Analysis Seta)5

Parameter

Placebo

(n = 226)

Fezolinetant 45 mg

(n = 226)

Family history of breast cancer in first degree relative or mutation of breast cancer gene (BRCA 1 or 2)

42 (18.6%)

40 (17.7%)

Relationship to participant

Relationship to participant

Relationship to participant

Relative, first degree

2 (4.8%)

1 (2.5%)

Mother, biological

24 (57.1%)

17 (42.5%)

Sister, full

9 (21.4%)

8 (20.0%)

Child, biological

1 (2.4%)

1 (2.5%)

Grandmother, biological

3 (7.1%)

6 (15.0%)

Aunt, biological

10 (23.8%)

12 (30.0%)

aSAF: All randomized participants who received at least one dose of study drug.

Ongoing clinical trials

Phase 3 study - HIGHLIGHT 1 (NCT06440967)5,6

  • HIGHLIGHT 1 is a trial to investigate the safety and efficacy of fezolinetant 45 mg for the treatment of moderate to severe VMS in women with Stage 0 to 3 hormone receptor-positive (HR+), either human epidermal growth factor receptor-2 positive (HER-2+) or negative (HER-2-) breast cancer who are receiving adjuvant endocrine therapy.
  • Participants must be receiving stable maintenance adjuvant endocrine therapy (tamoxifen 20 mg or daily aromatase inhibitors) with or without gonadotrophin releasing hormone (GnRH) agonists/antagonists for a minimum of four months, be planning to continue on the same adjuvant endocrine therapy (type, dose and brand) for the duration of the trial and not receiving chemotherapy.

Phase 4 study - OPTION-VMS (NCT06049797)7,8

  • OPTION-VMS is a real-world study to assess the change in VMS bother in women with a confirmed diagnosis of VMS who are initiating nonhormonal therapy, including fezolinetant.
  • Participants with non-metastatic (Stage 0 to 3) breast cancer who have been prescribed adjuvant endocrine therapy (tamoxifen or aromatase inhibitors) with or without GnRH analogues and have maintained a stable treatment regimen for ≥ 3 months can be included.

  1. Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. Available at: https://doi.org/10.1016/s0140-6736(23)00085-5.

  2. Johnson KA, Martin N, Nappi RE, et al. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. J. Clin. Endocrinol. Metab. 2023;108(8):1981-1997. Available at: https://doi.org/10.1210/clinem/dgad058.

  3. Neal-Perry G, Cano A, Lederman S, et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause. Obstet. Gynecol. 2023;141(4):737-747. Available at: https://doi.org/10.1097/aog.0000000000005114.

  4. Schaudig K, Wang X, Bouchard C, et al. Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial. BMJ. 2024;387(387):e079525. Available at: https://doi.org/10.1136/bmj-2024-079525.

  5. Data on file.

  6. Bouchard C, Miyazaki K, Tang CH, et al. Trial in Progress: A randomized, placebo-controlled, double-blind, phase 3 clinical study to investigate the efficacy and safety of fezolinetant for treatment of moderate-to-severe vasomotor symptoms (hot flashes) in women with stage 0 to 3 hormone receptor-positive breast cancer who are receiving adjuvant endocrine therapy [abstract].

  7. Neal-Perry G, Lederman S, Mancuso S, et al. OPTION-VMS: Preliminary Analysis of a Phase IV Observational, Real-World Study of Non-hormonal Pharmacotherapies for Bothersome Menopause-Associated Vasomotor Symptoms [poster]. The Menopause Society (TMS) 2025 Annual Meeting. Orlando, FL, USA. 2025.

  8. Maki PM, Mancuso S, Helbing M, et al. Preliminary Analysis of Work Productivity Outcomes in OPTION-VMS: A Phase IV Observational, Real-World Study of Non-hormonal Treatment for Bothersome Menopause-Associated Vasomotor Symptoms [poster]. The Menopause Society (TMS) 2025 Annual Meeting. Orlando, FL, USA. 2025.

If you are not able to find the information through the Search function, please contact our Medical Communications and Engagement Department by using any of the channels below:

Connect with Field Medical

Connect with Field Medical

Medical Science Liaisons (MSLs) and Medical Value and Access (MV&A) team members are available to help answer your scientific and health economic questions.

 

Submit an Inquiry

Submit an Inquiry

For any medical inquiries, please submit your question online to Astellas Medical Information or call or fax your inquiry.

Astellas Phone: 1-800-727-7003

Fax: 1-877-829-7942

Hours: M–F, 8 AM–4:30 PM (CT)

Report an Adverse Event or Product Complaint

Report an Adverse Event or Product Complaint

Report adverse events and product complaints to Astellas or FDA MedWatch.

Astellas Phone: 1-800-727-7003

FDA MedWatch: 1-800-FDA-1088

Hours: M–F, 8 AM–4:30 PM (CT)